

**THE ASSOCIATION BETWEEN PENTRAXIN 3
IN MATERNAL CIRCULATION AND
INTRAUTERINE GROWTH RESTRICTION:
A CASE CONTROL STUDY**

Thesis

Submitted for partial fulfillment of MD degree
in Obstetrics and Gynecology

Presented by

Rehab Mohamed Abd El Rahman

M.B., B.Ch. Ain Shams University 2006

M.Sc. OB/GYN Ain Shams University 2010

Under Supervision of

Prof. Essam-Eldin Mohamed Ammar

Professor of Obstetrics and Gynecology

Faculty of Medicine – Ain Shams University

Prof. Ahmed Ramy Mohamed Ramy

Professor of Obstetrics and Gynecology

Faculty of Medicine – Ain Shams University

Dr. Mostafa Ibrahim Ibrahim

Assistant Professor of Obstetrics and Gynecology

Faculty of Medicine – Ain Shams University

**Faculty of Medicine
Ain Shams University
2013**



*First and foremost, I would like to thank **ALLAH**, the Compassionate and the Merciful, for helping me finish this work, and for blessing me throughout my life by His Compassion and Generosity*

It is a pleasure to thank those who have made this thesis possible.

*Words fail to express my great indebtedness to **Professor Dr. Essam Ammar** Professor of Obstetrics and Gynecology, Ain Shams University, whose scientific guidance, continuous supervision, advice and fruitful criticism has enabled me to complete this work,*

*Likewise, I would like to thank my supervisor, **Professor Dr. Ahmed Ramy**, Professor of Obstetrics and Gynecology, Ain Shams University, for his valuable instructions, inspiring guidance and support throughout this work*

*I find no words by which I can express my deepest thanks and gratitude to my honored **Associate Professor Dr Moustafa Ibrahim**, Associate Professor of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams*

University, for his practical help and advice, and for making my thesis experience a productive one.

*I would like to express my sincere appreciation to **Dr. Mohamed Ibrahim Ellithy**, Lecturer of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University and **Dr. Rania Kabariti**, Associate professor of clinical pathology, Faculty of Medicine, Ain Shams University, for their support, effort, guidance and advice throughout the entire work.*

Lastly, and very importantly, I am forever indebted to my parents, my brother. Without their support, encouragement and understanding, this thesis would not have been possible.

This work was financially supported by Ain Shams Faculty of Medicine "Grants Office".

**Rehab Mohamed Abdel
Rahman**

LIST OF CONTENTS

Title	Page No.
List of tables	i
List of figures	ii
List of abbreviations	iii
Introduction	1
Aim of the Work.....	3
Review of Literature	
Chapter (1): Intrauterine Growth Retardation	4
1.1 Etiology:	5
1.2 Diagnosis:	8
1.3 Role of Doppler Ultrasound in diagnosis of IUGR:	12
1.4 Doppler ultrasound measurements:	16
1.5 Uterine artery Doppler ultrasound:	18
Chapter (2): Pentraxin-3 (PTX-3)	23
2.1 Introduction:	23
2.2 Chemical Structure:	24
2.3 Gene Regulation:	25
2.4 Mechanism of Action:	27
2.5 Biological Functions of Pentraxin-3	27
2.5.1. Role of PTX-3 in apoptosis	27
2.5.2. Role of PTX3 in innate immunity	28
2.5.3. Role of PTX-3 in fertility	30
2.5.4. Role of PTX-3 in Pregnancy	30
2.6 Clinical Utility of Pentraxin-3	30
2.6.1. Pentraxin-3 in Atherosclerosis and Cardiovascular Disorders.....	30
2.6.2. Pentraxin-3 in Chronic Kidney Disease (CKD)	31
2.6.3. Pentraxin-3 in Autoimmune Disorders	32
2.6.4. Pentraxin-3 in Lung Cancer	33
2.6.5. Pentraxin-3 in Inflammation and Infection	34
2.6.6. Pentraxin-3 in Pre-eclampsia	34
2.6.7. Pentraxin-3 in Intrauterine Growth Restriction (IUGR)	35

2.7 Assay of Pentraxin-3.....	36
2.7.1 Enzyme-linked immunosorbent assay (ELISA)	36
2.7.1.1 Sample specification.....	36
2.7.1.2 Principle of assay.....	37
2.7.1.3 Performance characteristics.....	38
2.7.2 Western blot analysis	38
2.7.2.1 Sample specification.....	38
2.7.2.2 Principle of assay.....	38
2.7.2.3 Performance characteristic	39
2.7.3 Semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR)	39
2.7.3.1 Principle of assay.....	39
2.7.3.2 Performance characteristic	41
Chapter (3): PTX3 as a marker in human pathology.....	42
3.1 Implantation and inflammatory networks:	42
3.2. PTX3 as a marker in human pathology:	45
Materials and methods	49
Results	53
Discussion	59
Summary.....	63
Conclusion.....	65
References	66

LIST OF TABLES

Tab. No.	Title	Page No.
Table (1):	Condition Associated with Intrauterine Growth Retardation	5
Table (2):	Comparison between women with and without IUGR.....	54
Table (3):	Comparison of receiver-operating characteristic (ROC) curves for diagnosis of IUGR using pentraxin 3 and multiple logistic regression model	56
Table (4):	Multiple logistic regression model for diagnosis of IUGR.....	57

LIST OF FIGURES

Figure No.	Title	Page No.
Figure (1):	Structure of first trimester placental villi.....	13
Figure (2):	Anatomy of the maternal-fetal interface.....	14
Figure (3):	Doppler indices. (S) peak systolic frequency shift (D) end diastolic frequency shift.	17
Figure (4):	(A) Normal flow velocity waveform from the uterine artery at 24 weeks of gestation. (B) Flow velocity waveform from the uterine artery at 24 weeks of gestation in a pregnancy with impaired placentation.....	19
Figure (5):	Changes in Umbilical Doppler waveforms in healthy pregnancies and in pregnancies with fetal growth restriction.....	21
Figure (6):	Structural organization of short and long pentraxins.....	25
Figure (7):	Steps of PCR.....	40
Figure (8):	PTX3 expression in human placenta and decidua	48
Figure (9):	Participants flow diagram.	53
Figure (10):	Boxplot showing pentraxin 3 level in both study groups.....	55
Figure (11):	Comparison of receiver-operating characteristic (ROC) curves for pentraxin 3 and the multiple logistic regression model for prediction of IUGR.	58

LIST OF ABBREVIATIONS

Abbreviations	Full term
a.umbilicalis ..	Arteria umbilicalis
a.uterinae	Arteriae uterinae
AC	Abdominal circumference
AFL.....	Amniotic fluid index;
AMI.....	Acute myocardial infarction
AUC	Area under the curve
BMI.....	Body mass index
BPD	Biparietal diameter
CI	Confidence Interval
COC	Cumulus oophorus cells in ovary
CRP.....	C-reactive protein
CS	Caesarean section
DCs	Dendritic cells
ECM.....	Extracellular matrix
ECs	Endothelial cells
EDTA.....	Ethylenediaminetetraacetic acid
ELISA	Enzyme-linked immunosorbent assay
FGR.....	Fetal growth restriction
FL	Femur length
GA.....	Gestational age
HIV.....	Human immunodeficiency virus
IUFGR.....	Intrauterine fetal growth restriction
IUGR.....	Intrauterine growth restriction
LPS	Lipopolysaccharide
<i>MDL</i>	Minimum detectable limit
NK	Natural killer
NPTXI	Pentraxin I
NPTXII.....	Pentraxin II
NSCLC.....	Non-small cell lung cancer
OMPs.....	Outer membrane proteins
OR.....	Odds ratio
PCR.....	<i>Polymerase chain reaction</i>
PI	Pulsatility index
PMNs.....	Polymorphonuclear cells
PTX3	Pentraxin 3

RI	Resistance index
ROC	Receiver-operating characteristic curve
<i>RT-PCR</i>	<i>Reverse transcriptase polymerase chain reaction</i>
S/D ratio	Systolic to diastolic ratio
SAP	Serum amyloid P-component
SCLC	Small cell lung cancer
<i>SDS-PAGE</i>	Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SGA	Small for gestational age
TGF- α	Tissue growth factor-alpha
TIMPs	Trophoblasts and their inhibitors
TLR.....	Toll-like receptor
TNF- α	Tumor necrosis factor- α
TSG-14.....	TNF-stimulated gene
UA-RI	Umbilical artery resistance index
UA-RI.....	Umbilical artery resistance index
US	Ultrasound.
VEGF	Vascular Endothelial Growth Factor

INTRODUCTION

The term, small for gestational age (SGA) fetus, describes that fetus with growth parameters below the 10th percentile. This term cannot differentiate between physiological and pathological smallness, distinction necessitates the assessment of the fetal growth potential. Intrauterine growth restriction (IUGR) describes the fetus who failed to reach its growth potential because of genetic and/or environmental causes. This term is not designated to describe a constitutionally small, but otherwise healthy fetus^[1]. It is essential to differentiate between a SGA fetus and a fetus with IUGR, as the latter is at risk for serious short and long term consequences while the earlier is not at high risk of perinatal mortality or morbidity if it is simply small because of constitutional elements^[2].

Pentraxin 3 (PTX3) is a well-known long pentraxin produced by many cells (epithelial cells, endothelial cells, fibroblasts, monocytes, polymorphonuclear leucocytes, macrophages, and dendritic cells)^[3,4]; it plays an essential role in female fertility, innate immunity, and inflammation. Recently, the role of PTX3 has been investigated in normal pregnancy, preeclampsia, intrauterine growth restriction, preterm labor, premature rupture of fetal membranes;



intraamniotic inflammation, recurrent miscarriage and implantation disorders^[5,6].

Antenatal diagnose of placental IUGR is challenging, the presence of an easily accessible marker in the maternal circulation, would help to classify SGA foetuses into high and low risk groups. Women with IUGR have increased PTX3 levels associated with altered placentation; however, this finding warrants further investigation^[7]. The aim of the current study was to compare the circulating PTX3 levels in pregnant women with and without IUGR.



AIM OF THE WORK

The aim of this study is to show the association between maternal circulating PTX3 level in normal pregnant women and those with IUGR.



Chapter One

INTRAUTERINE GROWTH RETARDATION

Distinguishing the constitutionally small fetus from the growth restricted fetus is a complex diagnostic and management problem, but is important. A constitutionally small fetus achieves its normal growth potential and has a good prognosis whereas the fetus whose growth potential is restricted is at increased risk of perinatal morbidity and mortality^[1]. Fetal growth restriction (FGR) that results from intrinsic fetal factors such as aneuploidy, congenital malformations, and fetal infection carries a guarded prognosis that often cannot be improved by any intervention. FGR related to uteroplacental insufficiency has a better prognosis, but is still associated with an increased risk of adverse outcome^[4].

The common definition of intrauterine growth retardation (IUGR) is a birth weight under the 10th Percentile.

Most authorities prefer to maintain the strict and more inclusive definition of IUGR as birth weight less than 10 percent of predicted fetal weight for gestational age. Using the 10th percentile as a standard result in overdiagnosis of IUGR. Other authors, however, have suggested using the 5th percentile to define IUGR infants^[2]. The counter argument in favor of a strict definition is that birth weight is probably the



single most important factor affecting neonatal morbidity and mortality and should be aggressively screened for. A lack of consensus among perinatologists makes it difficult to fully define the extent of IUGR and the subsequent effectiveness of interventions^[2].

1.1 Etiology:

Table (1): Condition Associated with Intrauterine Growth Retardation

Medical	Maternal	Infectious	Congenital
Chronic hypertension	Smoking	Syphilis	Trisomy 21
Preeclampsia early in gestation	Alcohol use	cytomegalovirus	Trisomy 18
Diabetes mellitus	Cocaine use	Toxoplasmosis Rubella	Trisomy 13
Systemic lupus erythematosus	Warfarin (Coumadin, Panwarfin)	Hepatitis B	Turner's syndrome
Chronic renal disease	Prior history of pregnancy with intrauterine growth retardation	HSV-1 or HSV-2	
Inflammatory bowel disease	Resting at altitude above 5,000 feet		
Severe hypoxic lung disease			

HSV = Herpes simplex virus, **HIV** = Human immunodeficiency virus.

Information from references 1 and 3

Historically, IUGR has been categorized as symmetric or asymmetric. Symmetric IUGR refers to fetuses with equally poor growth velocity of the head, the



abdomen and the long bones. Asymmetric IUGR refers to infants whose head and long bones are spared compared with their abdomen and viscera. It is now believed that most IUGR is a continuum from asymmetry (early stages) to symmetry (late stages)^[6].

Maternal causes of IUGR account for most uteroplacental cases. Chronic hypertension is the most common cause of IUGR. Moreover, the infants of hypertensive mothers have a three-fold increase in perinatal mortality compared with infants with IUGR who are born of normotensive mothers. Because of their significant risk, one author recommends delivering these infants by 37 weeks of gestational age^[4].

Preeclampsia causes placental damage that results in uteroplacental insufficiency. The pathogenic mechanism is thought to be a failure of trophoblastic invasion by maternal spiral arterioles by 20 to 22 weeks of gestation. This failure causes luminal narrowing and medial degeneration, leading to diminished blood flow to the developing infant. Consequently, these infants fail to grow normally^[5].

Infectious causes of fetal growth delay account for about 10 percent of all cases of IUGR. These causes include the "TORCH" group: Toxoplasma gondii, rubella, cytomegalovirus and herpes simplex virus types 1 and 2.